Biden’s Latest Drug Plan Picks Revive Push on ‘Pill Penalty’ Fix

The Biden administration’s selection of 15 new drugs for price negotiations is reigniting the call from opponents to amend how drugs can be selected for the Medicare program.

The Centers for Medicare & Medicaid Services unveiled Friday the list of 15 additional Part D drugs selected for a program that allows the US government to slash the cost of some of the most expensive and widely used drugs covered under Medicare.

The list included Novo Nordisk A/S blockblusters Ozempic and Wegovy; Astellas Pharma Inc.’s Xtandi; Pfizer Inc.’s Ibrance; and Bristol Myers Squibb Co.’s Pomalyst.

The pharmaceutical ...